Drug intelligence / Profile preview

Eladis

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Eladis is a pharmaceutical drug administered as 40 mg tablets, developed for the treatment of non-productive cough associated with acute respiratory viral infection with upper respiratory tract involvement or acute bronchitis. Clinical trials have demonstrated its efficacy and safety, showing a significant reduction in coughing attack frequency and earlier clinical cure compared to placebo.

Brand names: Eladis

Beyond the preview

Go deeper on Eladis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eladis.

Explore the full profile